Here are some key findings related to these targeted agents: (1) Inhibition of YES1: High‐throughput drug screening experiments in clear cell ovarian carcinoma revealed a synthetic lethal relationship between ARID1A mutations and the kinase inhibitor dasatinib, which targets YES1. The gene discussed is YES1; the disease is ovarian clear cell cancer.